Literature DB >> 18599087

Antigen-specific therapies in MS - Current concepts and novel approaches.

Andreas Lutterotti1, Mireia Sospedra, Roland Martin.   

Abstract

Induction of antigen-specific tolerance is a promising therapeutic approach for autoimmune diseases. Despite many successes in animal models, translation to the clinic has been hampered by lack of efficacy, disease exacerbation and hypersensitivity reactions. Novel approaches aim at inducing tolerance to several immunodominant antigens at the same time. Besides several key issues like the route of administration, dose of antigen and nature of antigen, antigen-specific therapies should be performed early in the disease course in order to block the diversification of autoreactive specificities and thereby prevent disease progression. It is essential that clinical trials are accompanied by appropriate immunologic analyses to be used either as a parameter to monitor safety and efficacy, but also to get a better understanding of the mechanisms of disease and the respective treatment approach. Here we will discuss the mechanisms of tolerance, the experience with trials in MS and present novel approaches.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18599087     DOI: 10.1016/j.jns.2008.05.021

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  11 in total

Review 1.  Challenges in the pursuit of immune tolerance.

Authors:  Gerald T Nepom; E William St Clair; Laurence A Turka
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

2.  Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis.

Authors:  Andreas Lutterotti; Sara Yousef; Andreas Sputtek; Klarissa H Stürner; Jan-Patrick Stellmann; Petra Breiden; Stefanie Reinhardt; Christian Schulze; Maxim Bester; Christoph Heesen; Sven Schippling; Stephen D Miller; Mireia Sospedra; Roland Martin
Journal:  Sci Transl Med       Date:  2013-06-05       Impact factor: 17.956

Review 3.  Targeting dendritic cells to treat multiple sclerosis.

Authors:  Manuel Comabella; Xavier Montalban; Christian Münz; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2010-08-17       Impact factor: 42.937

4.  A GMCSF-neuroantigen fusion protein is a potent tolerogen in experimental autoimmune encephalomyelitis (EAE) that is associated with efficient targeting of neuroantigen to APC.

Authors:  J Lori Blanchfield; Mark D Mannie
Journal:  J Leukoc Biol       Date:  2010-03       Impact factor: 4.962

Review 5.  Antigen-specific immunotherapy of autoimmune and allergic diseases.

Authors:  Catherine A Sabatos-Peyton; Johan Verhagen; David C Wraith
Journal:  Curr Opin Immunol       Date:  2010-09-17       Impact factor: 7.486

6.  A Novel Aza-MBP Altered Peptide Ligand for the Treatment of Experimental Autoimmune Encephalomyelitis.

Authors:  Nicole N M Trager; Jonathan T Butler; Jennifer Harmon; Joshua Mount; Maria Podbielska; Azizul Haque; Naren L Banik; Craig C Beeson
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

7.  Optimization of current and future therapy for autoimmune diseases.

Authors:  Lawrence Steinman; Joan T Merrill; Iain B McInnes; Mark Peakman
Journal:  Nat Med       Date:  2012-01-06       Impact factor: 53.440

8.  Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis.

Authors:  Andrea Harrer; Georg Pilz; Max Einhaeupl; Katrin Oppermann; Wolfgang Hitzl; Peter Wipfler; Johann Sellner; Stefan Golaszewski; Shahrzad Afazel; Elisabeth Haschke-Becher; Eugen Trinka; Joerg Kraus
Journal:  PLoS One       Date:  2012-02-20       Impact factor: 3.240

9.  Targeting Non-classical Myelin Epitopes to Treat Experimental Autoimmune Encephalomyelitis.

Authors:  Xiaohua Wang; Jintao Zhang; David J Baylink; Chih-Huang Li; Douglas M Watts; Yi Xu; Xuezhong Qin; Michael H Walter; Xiaolei Tang
Journal:  Sci Rep       Date:  2016-10-31       Impact factor: 4.379

10.  Beyond the Magic Bullet: Current Progress of Therapeutic Vaccination in Multiple Sclerosis.

Authors:  Barbara Willekens; Nathalie Cools
Journal:  CNS Drugs       Date:  2018-05       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.